Abstract
The COVID-19 pandemic has wreaked havoc globally, and there has been a particular concern for sub-Saharan Africa (SSA), where models suggest that the majority of the population will become infected. Conventional wisdom suggests that the continent will bear a higher burden of COVID-19 for the same reasons it suffers high burdens of other infectious diseases: ecology, socio-economic conditions, lack of water and sanitation infrastructure, and weak health systems. However, so far SSA has reported lower incidence and fatalities compared to the predictions of standard models and the experience of other regions of the world. There are three leading explanations, each with very different implications for the final epidemic burden: (1) low case detection, (2) differences in COVID-19 epidemiology (e.g. low R0), and (3) policy interventions. The low number of cases to date have led some SSA governments to relax these policy interventions. Will this result in a resurgence of cases? To understand how to interpret the lower-than-expected COVID-19 case data in Madagascar, we use a simple age-structured model to explore each of these explanations and predict the epidemic impact associated with them. We show that the current incidence of COVID-19 cases can be explained by any combination of the late introduction of first imported cases, early implementation of non-pharmaceutical interventions (NPIs), and low case detection rates. This analysis reinforces that Madagascar, along with other countries in SSA, remains at risk of an impending health crisis. If NPIs remain enforced, up to 50,000 lives may be saved. Even with NPIs, without vaccines and new therapies, COVID-19 could infect up to 30% of the population, making it the largest public health threat in Madagascar until early 2021, hence the importance of conducting clinical trials and continually improving access to healthcare.
Résumé La pandémie de COVID-19 a eu des conséquences néfastes partout dans le monde, et il y a une préoccupation particulière pour l’Afrique subsaharienne (ASS), où des modèles suggèrent que la majorité de la population sera infectée. Il est craint que le continent supportera un fardeau plus élevée de COVID-19 pour les mêmes raisons qu’il souffre d’avantage d’autres maladies infectieuses: écologie, conditions socio-économiques, manque d’infrastructures d’eau et d’assainissement, et faiblesse des systèmes de santé. Cependant, jusqu’à présent, l’ASS a rapporté une incidence et une mortalité bien inférieure à celle des prévisions des modèles pour cette région, ainsi qu’au nombre observé dans d’autres régions du monde. Il y a trois explications principales pour ce phénomène, chacune ayant des implications très différentes pour le fardeau épidémique final: (1) détection faible des cas, (2) différences dans l’épidémiologie COVID-19 (par exemple faible R0), et (3) interventions et politiques mises en place. Le faible nombre de cas à ce jour a conduit certains gouvernements d’ASS à assouplir ces interventions. Cela entraînera-t-il une résurgence de cas? Pour comprendre comment interpréter le fait que les cas COVID-19 rapportés sont plus faibles que prévu à Madagascar, nous utilisons un modèle de transmission structuré par groupe d’âge pour explorer chacune de ces explications et prédire l’impact épidémique qui leur est associé. Nous montrons que l’incidence actuelle des cas de COVID-19 peut s’expliquer par l’effet cumulé de l’introduction tardive des premiers cas importés, la mise en œuvre rapide d’interventions non pharmaceutiques (INP) et de faibles taux de détection des cas. Cette analyse renforce le fait que Madagascar, ainsi que d’autres pays d’Afrique subsaharienne, reste à risque d’une crise sanitaire imminente. Si les INP restent appliqués, jusqu’à 50 000 vies pourraient être sauvées. Même avec des INP, tant qu’il n’y aura pas des vaccins ni des nouvelles thérapies efficaces, COVID-19 pourrait infecter jusqu’à 30% de la population, ce qui constituerait la plus grande menace pour la santé publique à Madagascar jusqu’au début de 2021, d’où l’importance de la réalisation des essais cliniques et de l’amélioration continuelle de l’accès aux soins.
Summary Box
The lower-than-expected number of reported cases of COVID-19 in Madagascar can be explained by a combination of the relatively late introduction of the disease, low detection rates, and low transmission rates due to the early and effective implementation of non-pharmaceutical interventions that reduced contact rates.
COVID-19 is predicted to be the largest public health problem in Madagascar in 2020, but non-pharmaceutical interventions at an effectiveness similar to those seen in the first few months could save up to 50,000 lives.
Health systems in SSA remain at risk of an impending health crisis due to COVID-19, stressing the importance of ongoing clinical trials and improving health care access.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MVE was supported by a Graduate Research Fellowship (National Science Foundation).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All of the data used originated from a publicly available government website and is reported at the country-level.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is from the open dashboard on the Africa Centers for Disease Control and Prevention website.
